Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Proparacaine · Ophthaine, Ophthetic

Small molecule · developed by Apothecon

Approved FDA, Jul 1953
1 Registered trials

What is Proparacaine?

Proparacaine is a topical ophthalmic solution at 0.5% given as drops to the eye.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ophthaine, Ophthetic
Drug type
Small molecule
Therapy area
Ophthalmology
Developer
Apothecon
In trials of
HROW
FDA status
Approved as Ophthaine, Ophthetic (July 1, 1953), NDA008883
UNII
B4OB0JHI1X

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07456826 Phase 4 Diabetic Macular Edema (DME) Enrolling by invitation HROW

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Age-Related Macular Degeneration (AMD)Diabetic Macular Edema (DME)Diabetic Retinopathy (DR)Retinal Vein Occlusion

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.